Elahere (mirvetuximab soravtansine-gynx)

Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (FRα)-directed antibody–drug conjugate (ADC) linked to a microtubule inhibitor. It is indicated for the treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.